InspireMD (NYSE:NSPR) was given a new $5.00 price target on by analysts at Loop Capital.
InspireMD (NYSE:NSPR) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
InspireMD (NYSE:NSPR) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)